Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of apalutamide plus radiotherapy for high-risk localized or locally advanced prostate cancer
CTR20160491Phase 3Active
- Sponsor
- Aragon Pharmaceuticals
- Start
- Dec 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of apalutamide in prostate cancer (PCa), sponsored by Aragon Pharmaceuticals. Started Dec 2016; status: active.
02
Drugs
apalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on CTR20160491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20160491.